After identifying the intrinsic molecular subtypes (7, 8), the surrogate immunohistochemical panel to define the BL tumors became the triple-negative phenotype (negative for estrogen receptor, progesterone receptor, and HER2), along with cytokeratin 5/6 and/or EGFR-positivity (40). This evidence concerns the gene EGFR and Burkitt lymphoma.